Stockscreener 앱 받기
5.925
14.16%
0.735
시장 영업 전:
6.00
0.075
+1.27%
전일 마감가:
$5.19
열려 있는:
$5.38
하루 거래량:
1.25M
Relative Volume:
1.10
시가총액:
$461.62M
수익:
$14.79M
순이익/손실:
$-102.44M
주가수익비율:
-1.949
EPS:
-3.04
순현금흐름:
$-91.73M
1주 성능:
+10.54%
1개월 성능:
+34.51%
6개월 성능:
+54.30%
1년 성능:
+14.38%
1일 변동 폭
$5.355
$5.97
1주일 범위
$4.92
$5.97
52주 변동 폭
$2.41
$7.37
솔리드 바이오 Stock (SLDB) Company Profile
명칭
Solid Biosciences Inc
전화
617-337-4680
주소
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.925 | 404.35M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
솔리드 바이오 Stock (SLDB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 개시 | Needham | Buy |
| 2025-06-26 | 개시 | Citigroup | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-13 | 개시 | Wedbush | Outperform |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-07-15 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-06-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-03-28 | 개시 | William Blair | Outperform |
| 2024-03-15 | 개시 | Citigroup | Buy |
| 2024-03-14 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 개시 | H.C. Wainwright | Buy |
| 2021-07-12 | 개시 | Piper Sandler | Neutral |
| 2021-05-27 | 개시 | Jefferies | Buy |
| 2021-03-16 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 개시 | Barclays | Overweight |
| 2021-01-08 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 개시 | Evercore ISI | Outperform |
| 2019-08-29 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2019-08-19 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | 다운그레이드 | Goldman | Neutral → Sell |
| 2019-02-08 | 업그레이드 | Citigroup | Sell → Neutral |
| 2019-02-08 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 개시 | Citigroup | Sell |
| 2018-09-06 | 개시 | Credit Suisse | Neutral |
모두보기
솔리드 바이오 주식(SLDB)의 최신 뉴스
Solid Biosciences CEO Cumbo sells $55k in shares - Investing.com
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Solid Biosciences (SLDB) Receives Buy Rating Amid Competitive Ad - GuruFocus
SLDB Receives "Buy" Rating from Needham with $16 Target Price | SLDB Stock News - GuruFocus
How Solid Biosciences Inc. stock performs in rising dollar environment2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Solid Biosciences (Nasdaq: SLDB) issues 23,284 RSUs under 2024 inducement plan - Stock Titan
Solid Biosciences' SGT-212 Receives Rare Pediatric Disease Designation to Treat Friedreich's Ataxia - MarketScreener
Solid Biosciences (SLDB) Gains Key FDA Designation for Gene Ther - GuruFocus
Solid Biosciences Receives FDA Rare Pediatric Disease and Fast Track Designations for SGT-212, a Novel Gene Therapy for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences Inc. Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia - marketscreener.com
Franklin Resources Inc. Has $7.79 Million Position in Solid Biosciences Inc. $SLDB - MarketBeat
Is Solid Biosciences Inc. stock a bargain at current levels2025 Volatility Report & AI Enhanced Trading Alerts - moha.gov.vn
UBS Reaffirms Their Buy Rating on Credit Agricole (0HAI) - The Globe and Mail
SLDB Stock Up as FDA Clears IND for SGT-212 in Friedreich's Ataxia - MSN
Solid Biosciences (SLDB) Stock Analysis Report | Financials & Insights - Benzinga
Can Kennametal India Limited Deliver Relative Outperformance to SectorDebt-to-Equity Ratio Analysis & Access Free Tools and Start Investing - earlytimes.in
Is Solid Biosciences Inc a good long term investmentTake Profit Strategies & Free Discover Dynamic Stocks - earlytimes.in
Using Bollinger Bands to evaluate Solid Biosciences Inc.July 2025 Catalysts & Fast Gaining Stock Strategy Reports - newser.com
Why Solid Biosciences Inc. stock is trending among retail tradersJuly 2025 Opening Moves & Reliable Price Action Trade Plans - newser.com
How to forecast Solid Biosciences Inc. trends using time seriesGap Up & Weekly Market Pulse Updates - newser.com
What insider trading reveals about Solid Biosciences Inc. stockJuly 2025 Trends & Intraday High Probability Alerts - newser.com
Candlestick signals on Solid Biosciences Inc. stock todayMarket Sentiment Report & Long-Term Safe Investment Plans - newser.com
Strategies to average down on Solid Biosciences Inc.Watch List & Daily Stock Trend Watchlist - newser.com
What MACD signals say about Solid Biosciences Inc.July 2025 Recap & Reliable Entry Point Trade Alerts - newser.com
Is Solid Biosciences Inc. stock positioned for long term growth - newser.com
Solid Biosciences licenses next-generation AAV capsid to Andelyn By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid By Investing.com - Investing.com Nigeria
Solid Biosciences stock rises after licensing next-generation capsid - Investing.com
Solid Biosciences Grants Capsid AAV-SLB101 License to Andelyn Biosciences - MarketScreener
Andelyn Biosciences Signs Licensing Agreement with Solid Biosciences - Contract Pharma
Solid Biosciences (SLDB) Partners with Andelyn Biosciences for G - GuruFocus
Solid Biosciences licenses next-generation AAV capsid to Andelyn - Investing.com
Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 - The Manila Times
Solid Biosciences Licenses Next-Generation Capsid AAV-SLB101 to Andelyn Biosciences for Gene Therapy Development - Quiver Quantitative
Solid Biosciences Announces Licensing Agreement With Andelyn Biosciences For The Use Of Proprietary Next-Generation Capsid Aav-Slb101 - TradingView
What’s next for Solid Biosciences Inc. stock priceMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
How sustainable is Solid Biosciences Inc. stock dividend payoutPortfolio Performance Report & Daily Volume Surge Signals - newser.com
What momentum indicators show for Solid Biosciences Inc. stockJuly 2025 Closing Moves & Reliable Volume Spike Trade Alerts - newser.com
Applying sector rotation models to Solid Biosciences Inc.CPI Data & Accurate Technical Buy Alerts - newser.com
Does Solid Biosciences Inc. stock trade at a discount to peers2025 Short Interest & Reliable Momentum Entry Alerts - newser.com
How to monitor Solid Biosciences Inc. with trend dashboards2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Solid Biosciences director Ganot sells $13,505 in stock By Investing.com - Investing.com India
솔리드 바이오 (SLDB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.10%
1.10%
자본화:
|
볼륨(24시간):